CBD
A widely sold plant compound with a regulatory status most sites don't mention
CBD (cannabidiol) is one of over 100 compounds found in the cannabis and hemp plant. Unlike THC (tetrahydrocannabinol), CBD is not psychoactive -- it doesn't produce a "high." That distinction is real and well established, and it's the main reason CBD became so widely available after hemp (cannabis with under 0.3% THC) was federally legalized for cultivation under the 2018 Farm Bill.
What most CBD product pages don't tell you: separately from that hemp-legalization question, the FDA has concluded CBD does not meet the legal definition of a dietary supplement. That's a genuinely important piece of context most sites skip entirely -- see the regulatory callout above, and the FAQ below, for exactly what it does and doesn't mean.
The One Clear FDA-Approved Use
Epidiolex, a purified prescription CBD oral solution, is FDA-approved for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex in patients 1 year and older. This is a precisely dosed pharmaceutical drug, not a retail supplement -- but it's the strongest, clearest evidence base CBD has.
Anxiety (Real Signal, Still Limited)
A 2024 meta-analysis of 8 studies (316 participants) found a significant reduction in anxiety with CBD across generalized anxiety, social anxiety, and PTSD. The authors were upfront that the finding rests on a limited number of small trials and needs more research before it's considered settled.
Not Psychoactive
CBD does not produce intoxication or a "high" the way THC does. It interacts with the endocannabinoid system differently, which is why it's marketed for calm and stress support rather than any recreational effect.
Acute Situational Anxiety (Small Study)
A small 2011 trial gave a single 600mg dose of CBD to people with social anxiety disorder before a simulated public-speaking test and found it reduced anxiety compared to placebo. It was a one-time, single-dose study in 24 people -- suggestive, not proof of how daily use performs.
- Look for a third-party Certificate of Analysis (COA) before buying -- product content isn't FDA-verified
- Start low and go slow; there's no official dose to anchor to
- Never combine with medications without talking to your doctor or pharmacist first
- If seizures are the reason you're interested in CBD, ask your neurologist about Epidiolex specifically
The seizure evidence behind Epidiolex is genuinely strong -- large, controlled trials led to full FDA drug approval. The anxiety evidence is a different picture: a 2024 meta-analysis found a real, statistically significant effect across 8 studies and 316 participants, but the authors explicitly cautioned that the sample is still small and more trials are needed before treating it as settled. That's a meaningfully different confidence level than the seizure indication, even though both get marketed under the same "CBD" label.
How CBD Compares
| Ingredient | Best For | Key Difference |
|---|---|---|
| CBD | Stress, Anxiety (Early Evidence) | Not FDA-recognized as a supplement; real drug interaction risk |
| Ashwagandha | Stress, Cortisol | Legally a dietary supplement; larger, more consistent human trial base |
| L-Theanine | Calm Focus, Mild Relaxation | Non-sedating; works well alongside caffeine |
| Passionflower | Anxiety, Sleep Onset | Legally a supplement; comparable RCT evidence to a benzodiazepine for GAD |
These are the most common comparisons our customers ask about in-store.
1. U.S. Food and Drug Administration. FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD). Accessed 2026.
2. Han, K., Wang, J.Y., Wang, P.Y., & Peng, Y.C. (2024). Therapeutic potential of cannabidiol (CBD) in anxiety disorders: A systematic review and meta-analysis. Psychiatry Research, 339, 116049.
3. Bergamaschi, M.M., Queiroz, R.H.C., Chagas, M.H.N., et al. (2011). Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology, 36(6), 1219–1226.
4. Nasrin, S., Watson, C.J.W., Perez-Paramo, Y.X., & Lazarus, P. (2021). Cannabinoid Metabolites as Inhibitors of Major Hepatic CYP450 Enzymes, with Implications for Cannabis-Drug Interactions. Drug Metabolism and Disposition, 49(12), 1070–1080.
All references are peer-reviewed studies or position stands from reputable organizations.
Related Ingredients
Get Your Free Supplement Guide
“50 Supplement Myths Debunked” PDF + weekly evidence-based tips. 100% free.
Get Your Free PDF →No spam, ever. Unsubscribe anytime.